Product Description
Mechanisms of Action: FXa Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Thrombosis|Venous Thromboembolism|Acute Coronary Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00677053 |
TAK-442_202 | P2 |
Completed |
Acute Coronary Syndrome |
2010-06-01 |
2024-06-06 |
Primary Endpoints |
|
2008-000091-24 |
2008-000091-24 | P2 |
Completed |
Acute Coronary Syndrome |
2009-06-26 |
2022-03-12 |
Treatments |
|
NCT00641732 |
TAK-442_201 | P2 |
Completed |
Venous Thromboembolism |
2008-10-01 |
2024-06-06 |
Primary Endpoints|Treatments |
|
JapicCTI-101134 |
JapicCTI-101134 | P2 |
Completed |
Thrombosis |
None |
|||
JapicCTI-090865 |
JapicCTI-090865 | P2 |
Completed |
Thrombosis |
None |
Recent News Events
Date |
Type |
Title |
|---|